UCB (OTCMKTS:UCBJF) Shares Gap Up – Should You Buy?

UCB SA (OTCMKTS:UCBJF) gapped up before the market opened on Wednesday . The stock had previously closed at $269.30, but opened at $279.1050. UCB shares last traded at $279.1050, with a volume of 201 shares.

Wall Street Analyst Weigh In

Several analysts recently issued reports on UCBJF shares. Morgan Stanley restated an “overweight” rating on shares of UCB in a research note on Monday, September 8th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of UCB in a report on Monday, December 8th. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy”.

UCB Price Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The firm has a 50 day moving average of $276.72 and a 200-day moving average of $249.99.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.